Efficacy and safety of immune checkpoint inhibitors plus chemotherapy in esophageal cancer patients with liver metastases

doi:10.4251/wjgo.v18.i1.113440

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 1

This Article

(34)

(48)

(0)

(12)

(1)

(830)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Oncol. Jan 15, 2026; 18(1): 113440
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.113440

Full Size Figure Download Figure

Figure 1 Study flowchart. CMT: Chemotherapy; ICI: Immune checkpoint inhibitor; ORR: Objective response rate; DCR: Disease control rate; OS: Overall survival; PFS: Progression-free survival.

Citation: Dai EH, Que SH, Xu H, Zhong GQ, Zhang Z, Liang X, Zhai SW, Li YT, Wang JJ, Feng W. Efficacy and safety of immune checkpoint inhibitors plus chemotherapy in esophageal cancer patients with liver metastases. World J Gastrointest Oncol 2026; 18(1): 113440
URL: https://www.wjgnet.com/1948-5204/full/v18/i1/113440.htm
DOI: https://dx.doi.org/10.4251/wjgo.v18.i1.113440

Dai EH, Que SH, Xu H, Zhong GQ, Zhang Z, Liang X, Zhai SW, Li YT, Wang JJ, Feng W. Efficacy and safety of immune checkpoint inhibitors plus chemotherapy in esophageal cancer patients with liver metastases. World J Gastrointest Oncol 2026; 18(1): 113440 [PMID: 41607764 DOI: 10.4251/wjgo.v18.i1.113440]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.